←
Amanda Downey, MD285 posts
Amanda Downey, MD avatar

Amanda Downey, MD

@drdowneydoes

one over-caffeinated MD does stuff around SF 🌈 🏄‍♀️ 🚴 #tripleboard. associate prof. eating disorders & 💊 research. tweets are my own.

◷ Joined April 2018▧ 30 Photos and videos
Balázs Szigeti avatar
⟳ Amanda Downey, MD retweeted
Balázs Szigeti@psybalazs·7 Jul 2025

🍄🚨🍄🚨 Another day, another cool preprint from our group: An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression We enrolled individuals with #bipolar 2 (BD-II) currently experiencing a major #depressive episode. Participants must have had at least one unsuccessful medication trial of >6 weeks duration for BD-II over their lifetime. Four participants were on medications with potential #psilocybin interactions, which were tapered under psychiatric supervision to ensure clearance (≥5 half lives) before each administration. Psychiatric exclusions included current hypomania, history of psychotic disorder, moderate substance use disorder in the past 12 months, psychedelic use in the past six months and imminent risk of suicide. In this open-label, single-arm dose-escalation pilot trial, 14 participants received 10 mg of psilocybin, followed by 25 mg if depressive symptoms persisted. As usual participants underwent psychotherapy before, during, and after psilocybin administration sessions and were proactively monitored for adverse events. Depression and quality of life were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) and Quality of Life in Bipolar Disorder Questionnaire (QoL-BD), along with exploratory measures. Following the 10 mg session, MADRS scores significantly improved at all timepoints (A21: -12.7 [2.7], n=14, p<0.001) with 4 participants (28.5%) meeting remission criteria (MADRS ≤ 6) at 21 days after the 10mg dose. Non-remitting patients were given the 25 mg dose per protocol. After the 25 mg session, MADRS scores improved from baseline (B21: -18.6 [3.1], n=9, p<0.001). Sustained improvements in MADRS scores were observed at the 90-day assessment compared to baseline (AB90: -14.3 [2.8], n=12, p<0.001); Hedges’ g=1.9. QoL-BD scores improved 21 days following both the 10 and 25 mg administration sessions (A21: 35.5 [9.4], p<.001; B21: 55.9 [10.9], p<.001) and at the 90-day assessment (AB90: 31.2 [10.2], p=0.004); Hedges’ g=1.6. As expected, common adverse events included mild-to-moderate anxiety, nausea, and headache on dosing day. There were three notable adverse events: active suicidal ideation 37 days after an administration session, passive suicidal ideation 11 days after an administration session, and a hypomanic episode two weeks after an administration session. The small sample size and open-label design warrant cautious interpretation. The placebo response likely explains some of the observed benefits. However, in line with previous findings, baseline expectancy was not associated with clinical outcomes - to the best of my knowledge no psychedelic trial has provided empirical evidence for a positive expectancy bias at this point. Our results offer initial evidence that psilocybin therapy may be clinically beneficial in BD-II when administered under controlled conditions with a safety profile similar to studies in other patient populations. Full preprint: tinyurl.com/52n6uv4t 🙏+♥️to all coauthors: @drdowneydoes @thebandlab @ellenbradshaw and many others from the @UCSFPsychiatry 's @TrPR_Program! #psychedelic #trial #mentalhealthmonday #medicalinnovation

Post attachmentPost attachment
Michael Ostacher, MD, MPH avatar
⟳ Amanda Downey, MD retweeted
Michael Ostacher, MD, MPH@RecoveryDoctor·9 Jun 2025

Important to read this if you do work with psychedelic (and other consciousness-changing) drugs in the treatment of psychiatric disorders. Sobering, as they write. Great work by @psybalazs

🚨🍄 Major new preprint alert 🍄🚨 I think these will be important results. They are not going make me popular with my #psychedelic in-group, please do not shoot the messenger! The premise of this pre-registered meta analysis (osf.io/preprints/psyarxiv/vh…) is that it is biased to compare open-label trials to blind trials, it is only fair to compare open-label trials to other open-label trials. In the first case the open-label trials would gain an unfair advantage by benefitting from effects related to knowing the treatment. Therefore, we compared the efficacy of psychedelic-assisted therapy (PAT), which is open-label regardless of formal blinding to open-label traditional antidepressants (tAD; such as SSRIs/SNRIs where binded trials are very close to be truly blind) for the treatment of major depression. We tested 3 prior hypothesis (MCID: minimum clinically important difference, which we set to be 3-points on Hamilton depression scale; differences smaller than this are clinically meaningless): 1. At the primary endpoint, the estimated mean difference between PAT and open-label tAD will exceed the MCID, favoring PAT. 2. At the primary endpoint, the estimated mean difference between blinded and open-label tAD trials will exceed the MCID, favoring open-label administration. 3. At the primary endpoint, the estimated mean difference between blinded and open-label PAT trials will not exceed the MCID. In contrast with our prior hypothesis, we did not find PAT to be more effective than open-label tADs (H1). Not only was the difference not clinically meaningful, but practically there was no difference at all (~0.3 HAMD units). This finding means that tAD administered knowingly to patients, which is the case in real-life medical practice, is as effective as PAT. This result was robust across variations in study selection, including when we removed PAT trials on treatment-resistant depression. The improvement from baseline to endpoint was ~12 HAMD points for both treatments. We also assessed the impact of blinding in both PAT and tAD trials. We found that for tAD (H2), but not for PAT (H3), open label is associated with better outcomes than blinded treatment. However, even in the case of tAD, the difference was much lower than the MCID. How come hypothesis 1 failed, i.e. that PAT is no ore effective than open-label tADs, given that tAD trials are famous for small drug-placebo difference (~2.4 HAMD units), while PAT trials reported large effects (~7.3 large effects)? Well, there are two major factors: 1. As we show, open-label tAD is approximately ~1.2 HAMD units more effective than blinded treatment (H2). This effect can be interpreted as the influence of knowing one’s treatment assignment, such as positive expectancy. 2. A recent meta-analysis of depression trials found that relative to tAD trials, the placebo response is 4.0 HAMD points lower in psychedelic trials (Hsu et al., 2024). This suppressed placebo response leads to an inflated between-arm difference, as the treatment arm is measured against a lower floor. The sum of these two effects is 1.2 + 4.0 = 5.2 HAMD units which equals the difference of the reported between-arm effects (7.3 - 2.4 ~ 5), explaining why hypothesis 1 failed. The suppressed placebo response in PAT trials is likely attributable to the ‘know-cebo’ effect, i.e. the disappointment when patients realize they are in the control group. In PAT trials, this placebo suppression accounts for 4.0 / 7.3 ~ 55% of the total between-arm effect. In other words, ~55% of PAT’s between-arm effect is not explained by improvement in the treatment arm, but rather by the lack of improvement in the placebo arm. In summary, we found that for the treatment of depression, PAT is no more effective than open-label SSRIs/SNRIs. Our results for psychedelics are twofold: PAT demonstrated a robust and large therapeutic effects (~12 HAMD units), which justifies optimism. On the other hand, PAT’s lack of superiority compared to SSRIs/SNRIs under equal-unblinding conditions highlights the influence of blinding integrity and presents a sobering reality check for psychedelic medicine. In collaboration with @QuantPsychiatry and Hannah Barnett 🙏🫂 👆should be of interest to @MattBurkeMD @igoreckert @bita137 @Brainclinics @bruce_lambert @thelablab @IoanaA_Cristea @GregFonzo @MFPL6 @fredemag @n_sepeda @chchatham @LGHemkens @HolBjo @NaudetFlorian @NathanHuneke @RecoveryDoctor @iainjordan @GlynLewis9 @HengartnerMP @shayla__love @f_hieronymus @And_Cipriani @FlamelingJop @JD_Rosenblat @RickZeifman @AVoineskos @LukeJelen @TehseenNoorani @a_lisinski @PloederlM @ElliotMarseille @KingFranklinIV @JulesEvans11 @EikoFried @ExistWell @singletonion @_fernando_rosas @vincepsy @hartogsohn @MichielElk @JacobSAday @BWe1ss @sdpnayak @Colloca_Luana @JeremyHowick @mattbagg @TheBorisLab @BenColagiuri

Post attachment
Amanda Downey, MD avatar
Amanda Downey, MD@drdowneydoes·10 Jul 2024

🚨 Spread the word: our brief guide to the responsible and evidence-based use of psychopharmacology for patients with eating disorders is free to use!

📢 Exciting news! The AED Medical Care Standards Committee has just released "The AED Guide to Selecting Pharmacologic Treatments for Patients with #eatingdisorders." Want to read more? aedweb.org/resources/publica… #medicalcare #pharmacology #healthguidelines

0:06
Balázs Szigeti avatar
⟳ Amanda Downey, MD retweeted
Balázs Szigeti@psybalazs·5 Jun 2024

"Expectancy" and "unblind" was on full repeat yesterday during @US_FDA's discussion of @MAPS's #mdma trial, so here are a few points that I think can enrich the conversation: - I do not think its an issue if an intervention has some expectancy effects. The issue is if all or nearly all of it is expectancy. - That said, MDMA's effect sizes are large enough to accommodate both some expectancy and a drug effect. For example, in one phase 3 trial (tinyurl.com/362ws54a), the between-treatment difference was 0.9 standardized mean difference (SMD). That's a LARGE effect. Even if half of it is expectancy, that is still 0.45 SMD. For context, the the difference between placebo and SSRIs is 0.3 SMD (tinyurl.com/4csfvhbt). - Could 0.9 SMD be reasonably explained as just expectancy/unblinding? Did a quick calculation to estimate the unblinding effect on anxiety in our self-blinding microdose trial (tinyurl.com/4rnvp4y), a trial that has a lot of unblinding and clearly high expectancy. The effect was 0.5 SMD. - Expectancy effects are also expected in #psilocybin therapy just like for MDMA. The only trial that ever assessed it, found no evidence for expectancy effects in psilocybin treatment (tinyurl.com/3rb962am). I am not aware of a single MDMA trial that would have tried to measure it. I am open to the possibility that much of MDMA's observed effect is expectancy/unblinding, but where I found these arguments shallow yesterday is that there was zero effort trying to quantify the magnitude of expectancy and unblinding effects. You can measure these and provide context from other trials. Given the weight of the decision I expected more in-depth and quantitative arguments around these issues.

Amanda Downey, MD avatar
Amanda Downey, MD@drdowneydoes·25 Apr 2024

Minor, thoughtful modifications to existing safety protocols are likely to address the unique physiologic vulnerabilities seen in people with AN. Here we provide risk mitigation strategies.

Amanda Downey, MD avatar
Amanda Downey, MD@drdowneydoes·25 Apr 2024

While no study has explicitly examined the pharmacokinetic and pharmacodynamic properties of psilocybin in the setting of malnutrition, studies point to safety regardless of body weight.